{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IFN&page=12", "query": { "intervention": "IFN", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 878, "total_pages": 88, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IFN&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IFN&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T13:10:27.476Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00007995", "title": "Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "1999-07", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2013-02-04", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00007995" }, { "nct_id": "NCT01100528", "title": "Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ciliary Body and Choroid Melanoma, Medium/Large Size", "Ciliary Body and Choroid Melanoma, Small Size", "Iris Melanoma", "Recurrent Intraocular Melanoma" ], "interventions": [ { "name": "recombinant interferon alfa-2b", "type": "BIOLOGICAL" }, { "name": "dacarbazine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 38, "start_date": "2009-11-11", "completion_date": "2017-12-14", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01100528" }, { "nct_id": "NCT00402428", "title": "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "albumin interferon alfa-2b", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1331, "start_date": "2006-12", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2013-08-08", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402428" }, { "nct_id": "NCT00082719", "title": "Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer", "Urethral Cancer" ], "interventions": [ { "name": "Recombinant Interferon Alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 33, "start_date": "2003-12", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2015-05-14", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082719" }, { "nct_id": "NCT02194998", "title": "Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)", "type": "DRUG" }, { "name": "Dasabuvir (DSV)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 46, "start_date": "2015-09-16", "completion_date": "2018-11-13", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194998" }, { "nct_id": "NCT04356339", "title": "US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Interferon-beta-1b (BETASERON, BAY 86-5046)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2020-11-24", "completion_date": "2021-11-11", "has_results": false, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 1, "location_summary": "Whippany, New Jersey", "locations": [ { "city": "Whippany", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04356339" }, { "nct_id": "NCT00002657", "title": "SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 20, "start_date": "1995-05", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 86, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002657" }, { "nct_id": "NCT02269930", "title": "Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "peginterferon beta-1a", "type": "DRUG" }, { "name": "Rebif", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 30, "start_date": "2014-10", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-02-02", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269930" }, { "nct_id": "NCT00117637", "title": "BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Interferon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 189, "start_date": "2005-06", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 9, "location_summary": "Sacramento, California • Aurora, Colorado • Chicago, Illinois + 6 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Frederick", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT00117637" }, { "nct_id": "NCT04053673", "title": "Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "RBN-2397", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ribon Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2019-08-01", "completion_date": "2023-07-31", "has_results": false, "last_update_posted_date": "2023-03-28", "last_synced_at": "2026-11-07T13:10:27.476Z", "location_count": 11, "location_summary": "Aurora, Colorado • Denver, Colorado • New Haven, Connecticut + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04053673" } ] }